VerastemVSTM
VSTM
About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Employees: 78
0
Funds holding %
of 7,299 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
93% more call options, than puts
Call options by funds: $605K | Put options by funds: $314K
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
48% more capital invested
Capital invested by funds: $176M [Q4 2024] → $261M (+$85.1M) [Q1 2025]
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
9% more funds holding
Funds holding: 91 [Q4 2024] → 99 (+8) [Q1 2025]
6.22% more ownership
Funds ownership: 77.83% [Q4 2024] → 84.05% (+6.22%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
42%
upside
Avg. target
$13
130%
upside
High target
$15
166%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Sean Lee | 148%upside $14 | Buy Maintained | 9 May 2025 |
Jefferies Kelly Shi | 166%upside $15 | Buy Initiated | 10 Apr 2025 |
Mizuho Mara Goldstein | 42%upside $8 | Outperform Maintained | 9 Apr 2025 |
Guggenheim Michael Schmidt | 148%upside $14 | Buy Maintained | 24 Mar 2025 |
RBC Capital Gregory Renza | 148%upside $14 | Outperform Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about VSTM published over the past 30 days
Neutral
Business Wire
2 weeks ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
Positive
Zacks Investment Research
2 weeks ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
Neutral
Business Wire
2 weeks ago
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company's website at www.verastem.com. A.
Neutral
Business Wire
3 weeks ago
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1.
Neutral
Business Wire
3 weeks ago
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem's Phase 2 RAMP-201 clinical trial, which evaluated the combinati.
Neutral
Business Wire
1 month ago
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the first quarter ended March 31, 2025. “In the first quarter of 2025, we continued to make progress with our pipeline programs by exercising our option early to license VS-7375 from our partner GenFleet Therapeutics, completing enrollment in the initial c.
Neutral
Business Wire
1 month ago
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the fi.
Positive
Reuters
1 month ago
U.S. FDA approves Verastem's cancer therapy
The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.
Neutral
Business Wire
1 month ago
Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: H.C. Wainwright 3rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET 2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at.
Neutral
Business Wire
1 month ago
Verastem Oncology Announces $75 million Private Placement
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants.
Charts implemented using Lightweight Charts™